Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Neuro-Oncology|2014Cited by 147
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C. Widemann, Frank M. Balis, John P. Perentesis et al.|Neuro-Oncology|2014Cited by 114
Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Pediatric Blood & Cancer|2013Cited by 87
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C. Widemann, John P. Perentesis, Yao Lu et al.|Sarcoma|2019Cited by 74
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Clinical Cancer Research|2022Cited by 22